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Treatment of seizures in acute intermittent porphyria represents atherapeutic dilemma. Patients needing chronic therapy often 
experience acute porphyric attacks due to increased hepatic metabolism induced by the antiepileptic drugs themselves. Gabapentin 
is a new antiepileptic drug not appreciably metabolized by the liver in humans, and it appears to be safe and effective in the 
maintenance therapy of epilepsy in these patients. We report a patient affected by partial and generalized seizures in the course 
of acute intermittent porphyria, who was safely and successfully treated with gabapentin. 
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INTRODUCTION 
Acute intermittent porphyria (AIP) is a rare inherited 
disease, which results from a partial deficiency of the 
enzyme porphobilinogen (PBG) deaminase, leading to 
hepatic overproduction and urinary excretion of heme 
precursors PBG and delta-aminolevulinic acid (ALA)‘. 
Porphyric acute attacks are typically precipitated by 
drugs1v2. Seizures, either partial or generalized, af- 
fect from 5% to 15% of patients3v4. Most antiepileptic 
drugs (AEDs) induce porphyric attacks, thus seizures in 
AIP are frequently undertreated with benzodiazepines 
(BDZs). Gabapentin (GBP) is a new AED that does 
not induce hepatic metabolism and is theoretically in- 
dicated for antiepileptic maintenance therapy in All? 
We report a patient safely and successfully treated with 
GBP 
CASE REPORT 
The patient is a 23-year-old woman who started 
antiepileptic therapy with phenobarbital (PB) at 
100 mg/day after generalized status epilepticus since 19 
years of age. Six months later she was admitted to our 
hospital after three generalized tonic-clonic seizures. 
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Routine blood and CFS examinations were normal, as 
well as a brain CT scan. An EEG showed bilateral 
posterior slow waves and brain MRI showed bilateral 
frontal gyriform lesions without enhancement. During 
her hospital stay the patient had recurrent partial and 
generalized seizures and phenytoin (PI-IT) was added to 
the therapy at 300 mg/day. Two weeks later the seizures 
disappeared, but she developed confusion, lethargy and 
tetraparesis. PHT intoxication was suspected and the 
antiepileptic therapy was modified to carbamazepine 
(CBZ) alone at 600 mg/day. 
After an acute attack of abdominal pains and hal- 
lucinations, AIP was suspected and later confirmed 
by increased urinary ALA and PBG levels: ALA at 
276 mg/dl (n.v. < 0.55), PBG at 4.87 mg/dl (n.v. < 
0.15). Antiepileptic therapy was modified to valproic 
acid (VPA) at 400 mg/day. 
Until January 1996 she remained seizure-free and 
the EEG and brain MRI results normalized. Never- 
theless, she presented recurrent acute attacks of ab- 
dominal pains with steady increased urinary levels of 
ALA and PBG. We started a therapy of GBP alone 
at 1200 mg/day. At present she is seizure-free with 
no more abdominal pains, although the menstrual 
cycle has started again after 1 year of pharmacolog- 
ical amenorrhea. The levels of urinary ALA and PBG 
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reduced to 1.35 mg/dl and 1.9 mg/dl, respectively. The 
patient does not complain of any side-effects. 
DISCUSSION 
AIP is an autosomal dominant disease with low ge- 
netic penetration. Clinical symptoms usually appear 
with consumption of alcohol, drugs and hormones, fast- 
ing and other conditions’. 
Acute attacks in AIP are typically precipitated by 
drugs, inducing activation of the hepatic cytochrome 
P450 system. All ‘historical’ AEDs are known to 
be porphyrogenic and cannot be used in chronic 
antiepileptic therapy in AIP5. Alternative treatment 
with BDZs is unsatisfactory, because first, they are less 
effective and second, tolerance develops with chronic 
therapy. However, BDZs remain the first choice in the 
treatment of seizures during acute attack8. 
Bromides have been suggested for long-term treat- 
ment but, unfortunately, adverse effects on the skin, the 
gastroenteric and renal systems and on the CNS fre- 
quently occu?. GBP is a new AED structurally similar 
to the neurotransmitter gamma-aminobutyric acid. It is 
not metabolized in humans nor does it induce hepatic 
microsomal enzymes involved in drug metabolism7. 
Our patient experienced acute porphyric attacks 
while treated with PHT, CBZ and VPA, although 
seizure-free. Moreover, during PB therapy seizures 
continued. There was a clear clinical improvement fol- 
lowing GBP therapy and there was no doubt about its 
efficacy on seizures. Other epileptic patients have also 
been treated successfully with GBP8-‘0. Recent in vitro 
tests demonstrated that GBP does not lead to an in- 
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crease of porphyrins ” , therefore, this drug can be used 
safely and/or successfully in the treatment of patients 
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